The effectiveness of combined lipid-lowering therapy in patients after coronary artery revascularization

Abstract

Aim. Studying the results of treatment of patients by using combined lipid-lowering therapy
after coronary artery stenting in patients with acute myocardial infarction AMI.
Patients. A total of 64 patients underwent coronary artery revascularization with stenting
were selected. The patients were divided into two groups: group 1 (32 patients) received
lipid-lowering monotherapy (20 mg rosuvostatin), group 2 (32 patients) received combined
lipid-lowering therapy (20 mg rosuvostatin + 10 mg ezetimibe).
Results. In Group 1 patients, after 10 and 30 days, there was a slight improvement in lowdensity lipoprotein cholesterol (LDL-C) to 2.39±0.60 and 2.02±0.50 mmol/L, respectively
(p<0.05). In Group 2, LDL-C concentrations were 1.91±0.41 and 1.68±0.33 mmol/L after 10
and 30 days, respectively (p<0.05).
Conclusions: Combined lipid-lowering therapy (rosuvostatin + ezatemibe or rosulipplus)
improved the dynamics of clinical manifestations in patients with coronary artery disease,
indicators of central and peripheral hemodynamics after coronary artery stenting.